Aligos Therapeutics, Inc.

Historical 13F Holders

Symbol
ALGS
CUSIP
01626L204
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 01626L204 since 12/18/2024, newest first.

Filer % of Class Filed
Blatt Lawrence 13D 5.6% 6/24/2026
Event 6/16/2026
Blatt Lawrence 13G 5.1% 5/15/2026
Event 3/31/2026
Woodline Partners LP 13G/A Amendment 4 4.4% 5/15/2026
Event 3/31/2026
Woodline Partners LP 13G/A Amendment 3 5.4% 2/17/2026
Event 12/31/2025
Sio Capital Management, LLC 13G/A Amendment 1 5.5% 2/11/2026
Event 12/31/2025
Woodline Partners LP 13G/A Amendment 2 8.7% 11/14/2025
Event 9/30/2025
Woodline Partners LP 13G/A Amendment 1 9.8% 8/14/2025
Event 6/30/2025
Sio Capital Management, LLC 13G 5.5% 8/13/2025
Event 6/30/2025
Adage Capital Management, L.P. 13G/A Amendment 2
3.9% 8/12/2025
Event 6/30/2025
Alyeska Investment Group, L.P. 13G
10.0% 5/15/2025
Event 3/31/2025
EcoR1 Capital, LLC 13G/A Amendment 4
3.9% 5/15/2025
Event 3/31/2025
Woodline Partners LP 13G 5.2% 5/15/2025
Event 3/31/2025
Blatt Lawrence 13D/A Amendment 1 3.2% 3/12/2025
Event 3/10/2025
Armistice Capital, LLC 13G/A Amendment 2
4.99% 2/14/2025
Event 12/31/2024
Adage Capital Management, L.P. 13G/A Amendment 1
9.4% 2/12/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 1 4.00 $23.00
2026 Q2 31 2.29 M $13.2 M
2026 Q1 34 2.78 M $20.6 M
2025 Q4 40 2.81 M $26.2 M
2025 Q3 35 2.65 M $26.0 M
2025 Q2 39 2.71 M $19.5 M
2025 Q1 37 3.30 M $27.1 M
2024 Q4 34 1.62 M $64.5 M
2024 Q3 29 1.69 M $14.7 M